Continuing Medical Education Information
Accreditation and Designation Statement
The American Society of Clinical Oncology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This live activity has been approved for a maximum of 19.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Needs Statement
Currently, there are few educational opportunities that serve to provide a multidisciplinary approach toward the dissemination of practice information in prevention, screening, evaluation, and management of patients with genitourinary cancers. This 2013 Genitourinary Cancers Symposium offers an educational forum for the assessment of research and treatment advancements to improve medical knowledge and patient care competencies in urothelial carcinomas, penile, prostate, renal, and testis cancer.
Target Audience
This Symposium is designed for physicians and researchers interested in the prevention, screening, evaluation, and management of genitourinary cancers, including medical oncologists; urologists; radiation oncologists; radiologists; pathologists; epidemiologists, pharmacologists; and translational-oriented laboratory scientists.
This Symposium may also be of benefit to nurses, pharmacists, physician assistants, and other health care professionals involved in clinical care and research in this area.
Learning Objectives
Upon participation in this activity, attendees will be able to
- Analyze treatment options to individualize care for patients
- Evaluate diagnostic dilemmas for rare tumors and assess current treatment options and promising novel targets in initial stages of development
- Select the molecular imaging, adjuvant, and neoadjuvant therapeutic strategies to effectively manage and treat patients
- Interpret appropriate sequencing of treatment for patients with genitourinary cancers, based on imaging results, current surgical standards, and the predicted patient response to immunotherapy
- Appraise the use of molecular biomarkers and gene-expression data in genitourinary cancers to determine treatment options based on varying disease progression
- Determine when active surveillance provides a viable alternative to treatment based on the best available data and counsel patients regarding this approach when appropriate
This activity was planned in the context of the following ACGME competencies: Patient Care, Medical Knowledge, and Systems-based Practice.
Disclaimer and Unlabeled Usage Statement
The information presented is that of the contributing faculty and does not necessarily represent the views of the the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology, and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.
2013 Genitourinary Cancers Symposium Commercial Supporters
We gratefully acknowledge the following companies for supporting the education and science programs of the 2013 GU Cancers Symposium.
Astellas
Aveo
Medivation
Teva
Amgen
Bayer HealthCare Pharmaceuticals Inc. and Algeta US
Millennium: The Takeda Oncology Company
Onyx Pharmaceuticals
Pfizer Oncology
